LAUSANNE, Switzerland, Nov. 10, 2016 /PRNewswire/ -- Today, at the AMP 2016 Annual Meeting, Sophia Genetics, global leader in Data-Driven Medicine, and world-class Next-Generation Sequencing (NGS) assay developer ArcherDX, announced the signing of a new partnership to combine their technological solutions. The partnership will focus on oncology solutions addressing solid tumours and haematological disorders, as well as applications in liquid biopsy and immune repertoire profiling.
The agreement sees Sophia Genetics integrate the ArcherDX portfolio of NGS test kits into the Sophia DDM® analytical platform and offer the combined solutions to its ever-expanding network of hospitals and laboratories around the world. This partnership provides Sophia DDM® users with the unique experience of SOPHiA™ artificial intelligence making the most out of research samples prepared with ArcherDX sample preparation assays.
Research hospitals and laboratories will benefit not only from comprehensively detecting all kinds of genomic alterations in a single test, such as SNVs, INDELs, CNVs and gene fusions, but also from faster adoption of the solutions in clinical research and superior analytical performance. As more research laboratories use Sophia DDM® and upload sample genomic data, SOPHiA™ will continuously learn, providing ever more accurate and personalised characterizations of genomic alterations and treatments.
Jason Myers, Ph.D., CEO at ArcherDX, said, "This exciting partnership with Sophia Genetics will help to decentralize NGS-based testing in molecular laboratories. By joining forces, ArcherDX and Sophia Genetics are enabling international laboratories of all sizes using SOPHiA™ to access and report on cutting-edge applications that ArcherDX has developed, including gene fusions, liquid biopsies, and immune repertoire profiling."
Through Sophia DDM®, a clinical genomics community of more than 215 laboratories and hospitals in over 35 countries will have the opportunity to use Sophia Genetics and ArcherDX combined solutions to precisely identify disease-associated mutations with advanced genomic tests.
Jurgi Camblong, CEO and co-founder of Sophia Genetics commented, "This new partnership allows us to continue building the ecosystem around Sophia DDM®. We're committed to continuing to help unlock the power of data analysis for our fast-growing clinical genomics community. ArcherDX's purpose-built technologies for targeted NGS solutions will help SOPHiA™ generate precision results accessible on Sophia DDM®, thus further democratizing Data-Driven Medicine."
Sophia Genetics' and ArcherDX's partnership launches worldwide immediately, helping laboratories transition to NGS, obtain improved throughput, reduce hands-on time and generate reliable results.
About Sophia Genetics
Sophia Genetics, the global leader in Data-Driven Medicine, brings together expertise in genomics, bioinformatics, machine learning and data privacy. Based in Switzerland, the company is known for its medical standards and Swiss precision, accuracy and quality management. It offers health professionals performing clinical genomic testing: bioinformatics analysis, quality assurance and genomics data secure banking. Sophia Genetics does not hold personal information, and the data the company holds is anonymised. Developed by the company, SOPHiA™, the world's most advanced and used artificial intelligence for Data-Driven Medicine, helps laboratories reduce the cost, overcome complexity and fulfil quality constraints related to clinical genomics. For more information, please visit http://www.sophiagenetics.com / @SophiaGenetics / @JurgiCamblong.
About ArcherDX, Inc.
ArcherDX addresses the bottlenecks associated with using NGS in translational research by offering a robust platform for targeted sequencing applications.
Archer's targeted NGS assays generate highly enriched sequencing libraries to detect gene fusions, SNVs, indels and CNVs. Accompanied by the Archer Analysis suite of bioinformatics software, Archer's technology dramatically enhances complex mutation identification and discovery.
With product portfolios encompassing applications in gene fusions, DNA copy number, immune repertoire profiling, and liquid biopsy research, ArcherDX continues to lead in the development of high-impact applications in cancer research.
For Sophia Genetics
Weber Shandwick Switzerland
+41 79 127 63 58
+1 303 357 9001
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-partnership-between-sophia-genetics-and-archerdx-continues-to-democratize-data-driven-medicine-300360435.html